Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/d8/23/c0/d823c0cf-437c-210a-b04e-bfef99d23241/mza_2106615490319385882.jpg/600x600bb.jpg
ASX BRIEFS
Andrew Musgrave
183 episodes
6 days ago
Send us a text Corrosion, costs, and clean energy collide as we sit down with Nick O’Loughlin, Managing Director of Sparc Technologies, to unpack a focused plan for real-world impact. We trace how a graphene-based additive called ecosparc® aims to make protective coatings tougher for critical steel assets, and why a pilot plant north of Adelaide could change the economics of green hydrogen by using light, not large amounts of electricity. First, we dig into the coatings story. ecosparc® targ...
Show more...
Investing
Business
RSS
All content for ASX BRIEFS is the property of Andrew Musgrave and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text Corrosion, costs, and clean energy collide as we sit down with Nick O’Loughlin, Managing Director of Sparc Technologies, to unpack a focused plan for real-world impact. We trace how a graphene-based additive called ecosparc® aims to make protective coatings tougher for critical steel assets, and why a pilot plant north of Adelaide could change the economics of green hydrogen by using light, not large amounts of electricity. First, we dig into the coatings story. ecosparc® targ...
Show more...
Investing
Business
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/d8/23/c0/d823c0cf-437c-210a-b04e-bfef99d23241/mza_2106615490319385882.jpg/600x600bb.jpg
AROVELLA THERAPEUTICS LTD (ALA) - Killer Cells on a Mission: The iNKT Cell Cancer Therapy Story
ASX BRIEFS
16 minutes
2 months ago
AROVELLA THERAPEUTICS LTD (ALA) - Killer Cells on a Mission: The iNKT Cell Cancer Therapy Story
Send us a text Revolutionary cancer therapies are no longer confined to science fiction. Dr. Michael Baker, CEO of Arovella Therapeutics (ASX: ALA), reveals how the company's groundbreaking work with invariant natural killer T-cells (iNKT cells) is transforming cancer treatment through truly off-the-shelf cell therapies. Traditional cell therapies face significant hurdles – they're expensive, time-consuming to produce, and limited to treating the same patient they're derived from. Arovella's...
ASX BRIEFS
Send us a text Corrosion, costs, and clean energy collide as we sit down with Nick O’Loughlin, Managing Director of Sparc Technologies, to unpack a focused plan for real-world impact. We trace how a graphene-based additive called ecosparc® aims to make protective coatings tougher for critical steel assets, and why a pilot plant north of Adelaide could change the economics of green hydrogen by using light, not large amounts of electricity. First, we dig into the coatings story. ecosparc® targ...